DALLAS, July 14, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company Jazz Pharmaceuticals Inc. (JAZZ). The report includes a financial and investment analysis, comparative analysis, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Jazz Pharmaceuticals Inc. (Nasdaq:JAZZ) should be of particular interest to other drug manufacturers: Cephalon Inc. (Nasdaq:CEPH), Sepracor Inc. (Nasdaq:SEPR), Noven Pharmaceuticals Inc. (Nasdaq:NOVN) and Eli Lilly & Co. (NYSE:LLY).
It is available at: http://www.beaconequity.com/i/JAZZ/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Jazz Pharmaceuticals Inc. develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in phase III clinical trials comprises JZP-6 for the treatment of fibromyalgia.
In the report, the analyst notes:
"JAZZ's flagship product Xyrem is the only U.S. FDA-approved treatment for both excessive daytime sleepiness and cataplexy in patients with narcolepsy...The company has significantly increased U.S. sales of Xyrem since acquiring the rights to Xyrem in June 2005. JAZZ has licensed the rights to commercialize Xyrem in 54 countries outside of the U.S. In 2008, Xyrem net sales were $53.8 million.
"JAZZ reported positive preliminary top-line results from the clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The company announced that JZP-6 demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia."
To read the entire report visit: http://www.beaconequity.com/i/JAZZ
Join the fastest growing investment community at: http://www.stockhideout.com
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.